ADMA Biologics, Inc. (ADMA) Guidance & Earnings Results
On 2026-08-05 ADMA Biologics, Inc. reaffirmed guidance: "FY2026 total revenue $530-560M; FY2026 Adjusted Net Income $170-200M; FY2026 Adjusted EBITDA…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ADMAADMA Biologics, Inc.Follow ADMA — free
—
Price chart with a free account
- Market cap
- 2.4B
- P/E TTM
- 15.3
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 5 Aug 26 | Reaffirmed | FY2026 total revenue $530-560M; FY2026 Adjusted Net Income $170-200M; FY2026 Adjusted EBITDA $265-300M · full year |
| 6 May 26 | Lowered | FY2026 revenue $530-560M (down from prior); long-term guidance withdrawn · full year |
| 25 Feb 26 | Reaffirmed | FY2026 revenue >$635M, Adj. EBITDA >$360M; FY2029 revenue >$1.1B, Adj. EBITDA >$700M · full year |
| 5 Nov 25 | Raised | FY2025 revenue raised to $510M+ from $500M+; FY2026 revenue raised to $630M+ from $625M+; FY2026 adjusted EBITDA raised to $355M+ from $340M+ · full year |
| 6 Aug 25 | Reaffirmed | FY2025 total revenue >$500M; FY2026 total revenue >$625M; FY2025 Adjusted Net Income >$175M; FY2026 Adjusted Net Income >$245M; FY2025 Adjusted EBITDA >$235M; FY2026 Adjusted EBITDA >$340M; Pre-2030 annual revenue $1.1B+ · full year |
ADMA Biologics, Inc. — questions
- What guidance did ADMA Biologics, Inc. give?
- On 2026-08-05: "FY2026 total revenue $530-560M; FY2026 Adjusted Net Income $170-200M; FY2026 Adjusted EBITDA $265-300M"
- When does ADMA Biologics, Inc. report earnings?
- ADMA Biologics, Inc.'s next earnings report is expected on 2026-11-11.
Every figure on this page comes from ADMA Biologics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.